case_images: PMC10213279_01
case_images: Tissue biopsy next-generation sequencing showed (A) EGFR p.V774M mutation in exon 20 and (B) EGFR p.L833V mutation in exon 21.
case_images: fonc-13-1159308-g001.jpg
case_images: PMC10213279_01_fonc-13-1159308-g001.jpg
case_images: f1
case_images: Among them, EGFR p.V774M and EGFR p.L833V mutations are located in exon20 and exon21 respectively ( Figure 1 ).
case_images: The CT image changes of pulmonary primary tumor site, mediastinal lymph node metastasis, and liver metastases (A-E) before Almonertinib treatment in October 2021. (F-J) 1 month after Almonertinib treatment in December 2021. (K-O) 8 months after Almonertinib treatment in July 2022. (P-T) 13 months after Almonertinib treatment in December 2022.
case_images: fonc-13-1159308-g002.jpg
case_images: PMC10213279_01_fonc-13-1159308-g002.jpg
case_images: f2
case_images: Almonertinib 110 mg QD targeted therapy was administered. After one month of treatment, the lung mass, lymph nodes, and liver metastases were found to be smaller than before, and the pleural fluid was also reduced ( Figure 2 ).